Clinical Trial Results: Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of ARO-MMP7 inhalation solution in healthy participants and idiopathic pulmonary fibrosis patients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• ARO-MMP7 Inhalation Solution (Matrix metalloproteinase-7 inhibitor)

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-08-05